PCSK9 and cerebrovascular disorder: Clinical trials such as FOURIER (Giugliano et al., 2017b) and ODYSSEY OUTCOMES (Goodman et al., 2023) have demonstrated a noteworthy decrease in the risk of cerebrovascular diseases, encompassing ischemic stroke and recurrent ischemic stroke, through the administration of PCSK9 inhibitors.